AIMS: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. PATIENTS & METHODS: Data from 129 patients who received trabectedin as second-line treatment following failure with ananthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. RESULTS:Forty seven patients received one prior regimen (group A) and 82 patients receivedat least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. CONCLUSION: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.
RCT Entities:
AIMS: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. PATIENTS & METHODS: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. RESULTS: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. CONCLUSION: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.
Authors: Magda Cordeiro; José Manuel Casanova; Joana Rodrigues; João Freitas; Ruben Fonseca; Rui Caetano de Oliveira; Paulo Freitas Tavares Journal: Case Rep Oncol Date: 2020-02-11
Authors: Kamran Harati; Adrien Daigeler; Tobias Hirsch; Frank Jacobsen; Björn Behr; Christoph Wallner; Marcus Lehnhardt; Mustafa Becerikli Journal: Int J Mol Med Date: 2016-04-11 Impact factor: 4.101
Authors: Elisa Zanardi; Marco Maruzzo; Maria C Montesco; Anna Roma; Marco Rastrelli; Umberto Basso Journal: Anticancer Drugs Date: 2014-11 Impact factor: 2.248